For these reasons, targeting the PI3K pathway may mitigate several distinct steps leading to fibrotic progression and might represent a possible therapeutic option, providing promising treatment strategies for sepsis- and ARDS-induced pulmonary fibrosis. This evidence concerns the gene PIK3CD and Sepsis.